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EDITORIAL 
GOOD CLINICAL PRACTICE 
Clinical research is like a foundation stone 
upon which a tower of evidence is erected which 
helps in the better understanding of the cause 
of the disease, improvement in the diagnosis 
treatment and mechanism of human biology 
(Trauter,1997). It is only the systematically car-
ried out research which has made possible the 
increase in the life expectancy and decrease in 
human sufferings. While carrying out the clini-
cal research one must not treat human as 
biomachines but the rights, safety and well be-
ing of trial subjects should always prevail over 
the interests of science and society. 
Clinical trials require quite distinct shift in 
the attitudes and procedures from ordinary clini-
cal practice insofar as they require proactive 
approach to patient recruitment, enrolment and 
follow through as well as significant attention paid 
to the issue of documentation regulatory com-
pliance and error prevention (Keiv, 1997). 
Good clinical practice is an international 
ethical & scientific quality standard for design-
ing, conducting, recording and reporting trials 
that involve the participation of human subjects 
(ICH, 1997). 
All those people who are involved in any 
type of clinical trial must be aware about the ethi-
cal principles that have the origin in the declara-
tion of Helsinki. 
To investigate the knowledge of these 
principles concurring the clinical research among 
researching physicians and to compare this 
knowledge among the physicians in different 
research areas a survey based on 22 questions 
was send to 1000 hospital physicians in the 
Copenhagen area (Sovensen, 1997). 
Forty six percent and 304 of these were 
used for future analysis 821 replied that they had 
knowledge of good clinical practices neverthe-
less only 24% were able to recognize the mean-
ing of term "monitor", investigation .and "SOP" 
when asked about 6 different fictitious situations 
concerning making reports to an Ethical Review 
Board (ERB) only 33% replied correctly. This only 
shows the poor state of awareness about the 
guidelines of GCP among the researches. A 
better awareness can not be expected in Indian 
researches. The guidelines for GCP was devel-
oped with consideration of the current GCP of 
E.Union, Japan and U.S. as well as those of 
Austria, Canada and nordic countries & WHO. 
These guidelines -cover almost all the 
components of a clinical trial such as patient 
protection, responsibilities of the sponsors, in-
formation management, data processing and 
quality assurance. Observation of these guide-
lines and stands must be emphasized chiefly for 
the reasons of publication suitability and the 
international recognition of the research and 
development findings. 
THE PRINCIPLES OF GCP 
Before any trial is initiated forseeable risks 
and inconveniences should weight against 
anticipated benifit of the individual trial subject 
and society (Oberklaid & Wake, 1997). 
The available information on an investi-
gational products should be adequate to sup-
port the proposed trial which is then scientifi-
cally described in a detailed protocol which is to 
be received by IRB/IEC. 
Each individual involved in the trial should 
be qualified and proper informed consent is to 
be taken from every subject. 
All the trial information should be recorded 
handled and stored in a way that allows its 
accurate reporting, interpretation and verifica-
tion. Confidentiality should be maintained, all the 
investigational products should be manufac-
tured, handled and stored in accordance with 
good manufacturing practice (GMP). 
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THE IRB/IEC. (INTERNATIONAL REVIEW BOARD 
INDEPENDENT ETHICAL COMMITTEE) 
The IRB/IEC consists of a group of peo-
ple with a reasonable number of independent 
members, who collectively gave qualification 
and experience to review and evaluate the sci-
ence, medical aspects and ethics of the pro-
posed clinical trial. Minimum five members are 
required to form an IRB/IEC. An IRB/IEC should 
have at least one member whose area of inter-
est is in a non scientific and one member who is 
independent of the institution /trial site. 
There are Certain responsibility of IRB/ 
IEC. Important ones among them are : 
1) It has to obtain all the relevant documents 
concerning the trial. 
2) Safeguards the rights, safety and well being 
of all the trial subjects. 
3) Evaluates the qualification of the investiga-
tors. 
4) Conducts review of each trial at appropriate 
interval. 
5) Checks the ethical feasibility of any proposed 
trial and insures that open informed consent is 
taken from the trial subjects and that the trial 
conducted in accordance with the protocol and 
amendments. 
IRB/IEC should retain all the relevant 
records eg. written procedures, membership 
lists, submitted documents, minutes of meet-
ings and correspondence at least for 3 years 
after the completion of the trial, and provides 
them to the investigator, sponsor or regulatory 
authorities if required. 
THE INVESTIGATOR(S) 
1) The investigator(s) should be qualified and 
experienced enough to assure the responsibil-
ity for the proper conduct of the trial and should 
be thoroughly familial with the appropriate one 
of the investigational products as per the speci-
fication provided by the sponsor. The investiga-
tor should be aware of and comply with GCP 
and other regulatory requirements. 
2) The investigator should be adequately 
resourceful to properly conduct the proposed trial 
that is he should be able to recruit adequate 
number of trial subjects and staff who help in 
conducting the trial and it should properly train 
and inform the staff about the trial related duties 
and functions. 
3) The investigator should ensure that the proper 
medical care is provided to all the subjects for 
any adverse events. 
4) The investigator must obtain a written ap-
proval/option from the IRB/IEC for the trial pro-
tocol and it should provide to the IRB/IEC all 
the appropriate documents for review . 
5) The investigator must comply with the proto-
col agreed upon by the sponsor. Any deviation 
from the original protocol must be informed to 
the sponsor & IRB / IEC for the approval . 
6) The investigator must ensure that the investi-
gational procedure are used in accordance with 
the specification provided by sponsor and should 
ensure that subjects are following instructions 
properly. 
7)The investigator must follow the randomization 
procedures, follow blinding strictly if required and 
must break code as per the protocol specifica-
tion. 
8) For any trial either clinical or non clinical which 
involves human beings as subject a prior con-
sent is a must either from the subjects or legally 
acceptable representative. This consent which 
is an informed one is provided both orally as 
well as a written document contains all the per-
tinent information about the nature, procedure, 
associated risks and rights of the subject, is to 
be duly signed and dated by the subjects or his 
legally acceptable representative. 
Any information which gathered after the 
trial has started and as relevant should also be 
provided by the subjects and others associated 
with the trial. Any change in the protocol should 
also be informed particularly. 
The written informed consent form should 
address the purpose, procedures, risks & ben-
efit associated with the trial. 
The alternative method of treatment 
should also be informed that the subjects par-
ticipation is purely voluntary and the provision 
for the compensation in case of any adverse 
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event & anticipated expanses should also be 
conveyed. 
9) The investigator should ensure the accuracy 
completeness, legibility & timelines of data gath-
ered from the trial. 
10) Written summaries of the trial status should 
be provided to the IRB / IEC regularly. 
11) Any serious adverse event, death should be 
immediately informed to the sponsor & IRB / IEC. 
12) If the trial is terminated prematurily, should 
ensure appropriate therapy and follow up for sub-
jects. 
13) IRB/IEC should ba provided with the sum-
mary of the trials out come at the end. 
THE SPONSOR 
1) The sponsor is responsive fnr implementa-
tion and maintenance of the quality assurance 
and quality control systems to ensure that trial 
and conducted and data is generated docu-
mented and reported as according to the proto-
col. 
2) The sponsor may transfer its trial related du-
ties to a contact research organisation, but the 
ultimate responsibility lies with the sponsor. 
3) May designate qualified medical personnel 
to advise on related medical problem. 
4) The sponsor manages the trial by utilising 
appropriately qualified individuals for all the as-
pects of the trial such as appointing an independ-
ent data monitoring committee (IDMC) for han-
dling verification of data. All the documents are 
related to the trial should be at least maintained 
for 2 years after the discontinuation of the trial. 
5) The sponsor selects the qualified investiga-
tor/ institution and obtain an agreement from 
them for proper conductance of the trial accord-
ing to the protocol & with GCP. 
6) Provides insurance to the investigator against 
claims arising out of the trial and should super-
vise the compensation paid to the subjects when 
required. 
7) Confirms that the IRB / IEC is organized 
according to the GCP and has given its approva'l 
for conducting the trial. 
8) Should ensure that all the investigational prod-
uct are manufactured according to the good 
manufacturing practice (GMP) properly stored, 
packaged and coded if required. 
9) Ensure that the product are handled & sup-
plied properly in time and are stable over the 
period of study. 
10) The sponsor selects & appoints qualified 
monitors who verify that the rights of subjects 
are protected, data generated is accurate & com-
plete and the trial conducted in compliance with 
the protocol and GCP specification monitor acts 
as the main line of communication between the 
sponsor and investigator, it verifies the proper 
storage and handling of the investigational prod-
ucts. It also informs the investigator of any CRF 
entry error ommission or illegibility. Prepare the 
report regularly and submits it to the sponsor. 
CLINICAL TRIAL PROTOCOL & AMENDMENTS 
The contents of a trial protocol should in-
clude the following topics. 
1) Should contain all the general information 
about the identity and addresses of the sponsor, 
monitor, medical experts, investigator, qualified 
physician and of labs and departments associ-
ated with the trial. 
2) Background information about the investiga-
tional product and findings from the studies done 
on the products conducted earlier.Their known 
benefits and risks and description of the justifi-
cation of the route of administration dosages, 
regimen and treatment period. 
3) Objectives and purpose of the trial. 
4) Description of the trial design.(eg. double 
blind, single blind, placebo controlled etc.) 
5) Subjects inclusions / exclusions criteria ,with-
drawl criteria. ,, 
6) Treatment schedule of the products, other 
medication permitted or not permitted, efficacy 
and safety parameters associated with the trial. 
7) Statistics to be employed during and after the 
trial completion. 
8) Details about to be quality assurance, quality 
control ethical consideration, data handling & 
record keeping, financing and insurance and 
publication policies. 
In conclusion the scientific community J.K.TRIVEDI 
involved in all types of clinical trials must be 
aware of and comply with the specification 
described in details in the guidelines for GCP 
before conducting any trial.These guidelines not 
only safeguards the rights and safety of the trial 
subjects but it also guide clinicians (Ziegler & 
Parren,1995) for properly conducting any scien-
tific research and ensure the accuracy, legibility 
and acceptability of the out come derived out of 
these expensive and time consuming exercises 
which involves lot of man power and expecta-
tions (Scheen, 1998). 
It is also sometimes debated that the trial 
data obtained out of these trials is scientifically 
credible but the conclusions reached by the trial 
with very stringent exclusion criteria do not 
reflect the practice environment in which the 
products will be prescribed by the clinician 
(Yastrubetskaya etal.,1997) this raises the ques-
tion of the relevance of good clinical research 
practice and good clinical practice guidelines to 
the reality of GCP beyond the trial situation. 
The GCP can not only come from science 
alone or only from the personal experience. 
(Fugelli,1998) as using only scientific wisdom 
replaces the human touch, destiny and hope by 
modern scientific megalomania and only the 
personal wisdom blinds the clinician with biases. 
So GCP is an amalgam of science and practical 
wisdom gained by personal experiences. 
J.K.Trivedi 
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